Revolution Medicines, Inc. Paid-in-Kind Interest
Revolution Medicines, Inc. (RVMD) reported Paid-in-Kind Interest of $35.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-05
- Revolution Medicines, Inc. paid-in-kind interest for the quarter ending 2026-06-30 was $22.90M, a 2544.23% increase year-over-year.
- Revolution Medicines, Inc. paid-in-kind interest for the quarter ending 2026-03-31 was $12.20M.
- Revolution Medicines, Inc. paid-in-kind interest for the quarter ending 2025-12-31 was $11.94M.
- Revolution Medicines, Inc. paid-in-kind interest for the quarter ending 2025-09-30 was $11.43M.
- Revolution Medicines, Inc. paid-in-kind interest for fiscal 2025 was $24.23M.
- Revolution Medicines, Inc. paid-in-kind interest for fiscal 2024 was $0.00.
- Revolution Medicines, Inc. paid-in-kind interest for fiscal 2023 was $0.00.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $35.10M 10-Q · filed 2026-08-05 | $47.03M derived: sum of 3 quarters · filed 2026-08-05 | $58.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $12.20M 10-Q · filed 2026-05-06 | $24.13M derived: sum of 2 quarters · filed 2026-05-06 | $35.56M derived: sum of 3 quarters · filed 2026-05-06 | $36.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $11.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $23.36M derived: sum of 2 quarters · filed 2026-02-25 | $24.23M derived: sum of 3 quarters · filed 2026-08-05 | $24.23M 10-K · filed 2026-02-25 |
| 2025-09-30 | $11.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $12.29M derived: sum of 2 quarters · filed 2026-08-05 | $12.29M 10-Q · filed 2025-11-05 | $12.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $866.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $866.00K 10-Q · filed 2026-08-05 | $866.00K derived: sum of 3 quarters · filed 2026-08-05 | $866.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |